CARUSO JAMES V 4

What Happened
James V. Caruso, President & CEO and a director of Cellectar Biosciences (CLRB), was granted a derivative award of options covering 250,000 shares. The filing lists the acquisition at $0.00 (derivative instrument); the grant was contingently made May 28, 2026 and became effective when stockholders approved the amended 2021 Stock Incentive Plan on July 7, 2026. No immediate sale or exercise occurred — this is an equity award, not a cash purchase or disposition.

Key Details

• Transaction date: reported for period 2026-07-07; Form 4 filed 2026-07-08 (timely).
• Award: options for 250,000 shares; filing shows $0.00 per share (derivative). The filing excerpt does not state an exercise/strike price.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: (F1) Grant was contingent on shareholder approval (approval received 7/7/2026). (F2) Vesting: three years from May 28, 2026 — 1/3 vests on first anniversary of May 28, 2026, then the remainder vests in 24 equal monthly installments over the following 24 months.
• Timeliness: filing appears timely (filed the next day).

Context
This was an option award (derivative grant) that vests over time; such awards give the executive a future right to acquire stock subject to vesting and any exercise price, and do not represent an immediate purchase or sale. Because the award vests gradually, the shares are not fully available for sale until vesting conditions are met. Awards are common executive compensation and should be interpreted differently from open-market purchases (which are stronger, immediate bullish signals).